

This is an abridged prospectus containing salient features of the Red Herring Prospectus dated June 13, 2024 (the “RHP”). You are encouraged to read greater details available in the RHP (Download link: www.medicamenorganics.com). Unless otherwise specified all capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the RHP.

THIS ABRIDGED PROSPECTUS CONSISTS OF TEN PAGES. PLEASE ENSURE THAT YOU HAVE RECEIVED ALL THE PAGES.



MEDICAMEN ORGANICS LIMITED

CIN: U74899DL1995PLC066416; Date of Incorporation: March 15, 1995

Registered Office	Contact Person	Email and Telephone	Website
10 Community Centre, No 2 Ashok Vihar, Phase II, New Delhi, Delhi, 110052, India	Ms. Varsha Bansal, Company Secretary and Compliance Officer	Email-id: cs@mediorganics.in ; Tel.: +91-9818222845	www.medicamenorganics.com

PROMOTERS OF THE COMPANY

MR. BAL KISHAN GUPTA AND MR. ASHUTOSH GUPTA

Details of Offer to Public

Type of Issue (Fresh/ OFS/Fresh & OFS)	Fresh Issue Size (by no. of shares or by amount in Rs)	OFS Size (by no. of shares or by amount in Rs)	Total Issue Size (by no. of shares or by amount in Rs)	Issue Under 6(1)/ 6(2)	Share Reservation			
					QIB	NII	RII	Market Maker
Fresh Issue	Up to 31,00,000 Equity Shares	Nil	Up to 31,00,000 Equity Shares	This issue is being made in terms of Regulation 229(2) of Chapter IX of the SEBI (ICDR) Regulations, 2018 as amended.	Not more than 14,60,000 Equity Shares	Not less than 4,40,000 Equity Shares	Not less than 10,28,000 Equity Shares	Up to 1,72,000 Equity Shares

These equity shares are proposed to be listed on NSE Emerge (i.e. SME platform of National Stock Exchange of India Limited).

DETAILS OF OFFER FOR SALE, SELLING SHAREHOLDERS AND THEIR AVERAGE COST OF ACQUISITION – NOT APPLICABLE AS THIS IS A FRESH ISSUE OF EQUITY SHARES

Price Band, Minimum Bid Lot & Indicative Timelines

Price Band*	Rs. 32/- to Rs. 34/- Per Equity Share of face value of Rs. 10/- each.
Minimum Bid Lot Size	For details of minimum bid lot size, please refer to price band advertisement to be published in two national daily newspapers (one each in English and in Hindi) with wide circulation and one daily regional newspaper with wide circulation at least two working days prior to the Bid / Issue Opening Date.
Anchor Portion Offer Opens/Closes on**	Thursday, June 20, 2024
Bid/Offer Open On	Friday, June 21, 2024
Bid/Closes Open On	Tuesday, June 25, 2024
Finalisation of Basis of Allotment	On or before Wednesday, June 26, 2024
Initiation of Refunds	On or before Wednesday, June 26, 2024
Credit of Equity Shares to Demat accounts of Allottees	On or before Thursday, June 27, 2024
Commencement of trading of Equity Shares	On or before Friday, June 28, 2024

*For details of price band and Basis of Issue Price, please refer to price band advertisement and page 86 of RHP.

**Our Company, in consultation with the BRLMs, consider participation by Anchor Investors in accordance with the SEBI (ICDR) Regulations. The Anchor Investor Bidding Date shall be one Working Day prior to the Bid/Issue Opening Date i.e. Thursday, June 20, 2024.

The Weighted average cost of acquisition of all Equity Shares transacted over the trailing eighteen months from the date of RHP

Period	WACA (in ₹)	Floor Price (84)	Cap Price (89)
a) Weighted average cost of acquisition of primary/new issue 18 months prior to RHP		NA*	
b) Weighted average cost of acquisition for secondary sale/acquisition 18 months prior to RHP		NA**	
c) WACA of Equity Shares based on Primary issuances undertaken during the 3 immediately preceding years*		NA#	
WACA of primary / new issue acquisition	14.61	[●]	[●]
WACA of secondary acquisition	29.99	-	-

*Information of Cap Price will be included after finalization of the Price Band

WACA: Weighted Average Cost of Acquisition shall be calculated on fully diluted basis for the trailing eighteen months from the date of RHP.

RISKS IN RELATION TO THE FIRST ISSUE

This being the first public offer of the Equity Shares of our Company, there has been no formal market for the Equity Shares. The face value of each Equity Share is ₹ 10/-. The Floor Price, Cap Price and Offer Price as determined by our Company in consultation with the Book Running Lead Manager, on the basis of the assessment of market demand for the Equity Shares by way of the Book Building process, as stated under “Basis for Issue Price” on page 86 should not be considered to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active or sustained trading in the Equity Shares nor regarding the price at which the Equity Shares will be traded after Listing.

GENERAL RISK

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue, including the risks involved. The Equity Shares in the Issue have not been recommended or approved by the Securities and Exchange Board of India (“SEBI”), nor does SEBI guarantee the accuracy or adequacy of the contents of this Red Herring Prospectus. Specific attention of the investors is invited to “Risk Factors” beginning on page 27 of the Red Herring Prospectus.

PROCEDURE

You may obtain a physical copy of the Bid-cum-Application Form and the RHP from the stock exchange, syndicate members, registrar to the issue, share transfer agents, depository participants, stock brokers, underwriters, bankers to the issue, investors’ associations or Self Certified Syndicate Banks.

If you wish to know about processes and procedures applicable to this issue, you may request for a copy of the RHP and/or the General Information Document (GID) from the BRLM’s or download it from the website of the Stock Exchange i.e. www.nseindia.com and the BRLM at www.gyrcapitaladvisors.com

PRICE INFORMATION OF BRLM’s*

Sr. No.	Issue name	Name of Merchant Banker	+/- % change in closing price, [+/- % change in closing benchmark]- 30 th calendar days from listing	+/- % change in closing price, [+/- % change in closing benchmark]- 90 th calendar days from listing	+/- % change in closing price, [+/- % change in closing benchmark]- 180 th calendar days from listing
1.	Naapbooks Limited	GYR Capital Advisors Private Limited	-16.22%	-29.73%	-18.905%
2.	Ascensive Educare Limited		0.00%	-30.00%	14.61%
3.	Achyut Health Care Limited		0.00%	4.75%	-9.75%
4.	Dhyaani Tile and Marblez Limited		19.61%	82.35%	11.764%
5.	Veekayem Fashion and Apparels Limited		59.96%	22.67%	0.17%
6.	JFL Life Sciences Limited		-29.01%	-38.52%	-40.98%
7.	Sabar Flex India Limited		54.54%	44.54%	32.27%
8.	Mafia Trends Limited		-8.57%	-26.78%	-52.82%
9.	Pritika Engineering Components Limited		35.69%	-4.59%	8.62%
10.	Uma Converter Limited		21.21%	-6.10%	-12.88%
11.	Anlon Technology Solutions Limited		84.40%	-1.61%	163.95%
12.	Agarwal Float Glass India Limited		-9.52%	-14.29%	-13.09%

13.	Mcon Rasayan India Limited		87.5%	157.13%	230.25%
14.	Essen Speciality Films Limited		37.38%	21.00%	94.85%
15.	Srivari Spices & Foods Limited		199.17%	291.78%	591.90%
16.	Basilic Fly Studio Limited		194.07%	-214%	294.79%
17.	Maitreya Medicare Limited*		65.36%	122.38%	-
18.	Trident Techlabs Limited*		469.71%	125.91%	-
19.	Kay Cee Energy & Infra Limited*		608.24%	-14.47%	-
20.	Maxposure Limited*		170.60%	-35.93%	-
21.	Thaai Casting Limited*		-20.24%	-0.94%	-
22.	Koura Fine Diamond Jewelry Limited*		-35.05%	1.57%	-
23.	Naman In-Store (India) Limited*		-	-	-
24.	ABS Marine Services Limited*		-	-	-
25.	HOAC Foods India Limited*		-	-	-

Source: Price Information www.bseindia.com & www.nseindia.com Offer Information from respective Prospectus.

** Companies have been listed on November 07, 2023 December 29, 2023, January 05, 2024, January 23, 2024, February 23, 2024, March 14, 2024, April 02, 2024, May 21, 2024 and May 24, 2024 hence not applicable.

‘Name of BRLM and contact details (telephone and email id) of each BRLM	GYR Capital Advisors Private Limited Address: 428, Gala Empire, Near JB Tower, Drive in Road, Thaltej, Ahmedabad -380 054, Gujarat, India. Tel No+91 87775 64648 Email: info@gyrcapitaladvisors.com Contact Person: Mohit Baid
Name of Syndicate Members	GYR Capital Advisors Private Limited
Name of Market Makers	Giriraj Stock Broking Private Limited
Name of Registrar to the Offer and contact details (telephone and email id)	KFIN TECHNOLOGIES LIMITED Selenium Tower- B, Plot 31-32, Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad-500 032, Telangana, India. Tel No.: +91 40 6716 2222 Fax: +91 40 2343 1551 Website: www.kfintech.com Email: nvl.ipo@kfintech.com ; Investor Grievance Email: einward.ris@kfintech.com Contact Person: Mr. M Murali Krishna SEBI Registration No.: INR000000221
Name of Statutory Auditor	N C Raj & Associates, Chartered Accountants
Name of Credit Rating Agency and therating or grading obtained if any	Not Applicable
Name of Debenture trustee, if any.	Not Applicable
Self-Certified Syndicate Banks	The list of banks is available on https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes
Non-Syndicate Registered Brokers	You can submit Bid cum Application Forms in the Issue to Non Syndicate Registered Brokers at the Non Syndicate Broker Centres. For further details, see section titled “ Issue Procedure ” beginning at page 217 of the RHP
Details regarding website address(es)/ link(s) from which the investor can obtainlist of registrar to issue and share transfer agents, depository participants and stock brokers who can accept application from investor (as applicable)	https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes

PROMOTERS OF THE ISSUER COMPANY

Sr. No.	Name	Individual/ Corporate	Experience & Educational Qualification
1	Bal Kishan Gupta	Individual	Bal Kishan Gupta is the Promoter, He is the Chairman and Managing Director of our Company. He holds a bachelor of Arts degree. He has more than 35 years of experience in manufacturing, exports and distribution of pharmaceutical products. He has been associated with our Company since inception and is responsible for expanding business horizons, corporate strategy, leadership and management, financial performance across verticals, stakeholder relations, innovation and growth, identifying new opportunities and risk management of our Company. He has been General Secretary of IDMA (India Drugs Manufactures Associations), it is the most reputed association in India for pharmaceutical manufactures.
2	Ashutosh Gupta	Individual	Ashutosh Gupta is the Promoter and a Whole-time Director of our Company. He holds the degree of Bachelor of Business Administration from Guru Jambheshwar University, Hissar. He has experience in this field of 18 years he earlier worked with listed Company names Medicamen Biotech Limited and later joined Medicamen Organics Limited. He has been awarded with the degree of Honorary Doctorate in contribution in Export of Pharma Industry in the year 2021. He has been Chairman of Pharmexcil (Pharmaceuticals Export Promotion Council of India) from 2014-2016, a Government of India Council, specifically created for promotion of pharmaceutical exports from India.

BUSINESS OVERVIEW AND STRATEGY

Company Overview: We are engaged in developing, manufacturing and distribution of broad range of pharmaceutical dosage including generic dosage in form of Tablets, Capsules, Oral Liquids, Ointments, Gel, Syrups, Suspension and Dry powders for government (including both state and central governments) and private institutions as contract manufacturer / third party manufacturer. We market our product to private pharma companies in domestic as well as international markets through third party distributors or on loan license basis. Further, our Company is also strategically focusing on establishing a direct presence in international market for an instance in fiscal 2023 and 2024, we have directly exported our product in Burundi. We have a track record of operating B2B model which covers contract manufacturing model. Our products are marketed across India as well as African, CIS and south East Asian Countries like Congo, Benin, Camer, Togo, Senegal, Burkina Faso, Philippines, Myanmar, Mozambique, Togo, Burundi, Kyrgyzstan and Kenya by our third-party distributor.

We have 2 WHO GMP approved manufacturing facilities located at 60 and 61, Sector 6A, I.I.E. SIDCUL, Ranipur, Haridwar- 249403, Uttarakhand spread across 21,536 Sq. Ft. Our manufacturing facilities are capable of producing pharmaceutical formulations and products and has fully equipped quality control department with experienced and qualified staff to facilitate smooth manufacturing process. We have in-house testing laboratory and necessary infrastructure to test our raw materials and finished products to match the quality standards. We are ISO 9001:2015 certified company. Our core strength lies in product development and documentation, we are regularly engaged in research and development and launching new products. This gives us an exhaustive product list as well as fair pricing in the market. Our product portfolio consists of 84 products and comprises of wide range of drugs like, Anti-Bacterial, Anti-Diarrheal, Anti-Fungal, Anti-Malarial, Anti-Diabetic, Proton Pump Inhibitor, Anti-Histamine, Anti-Hypertensive drugs, Anti-Lipidemic Drug, Anti-Parasitic, Multivitamin, Multimineral and Nonsteroidal anti-inflammatory drug (NSAIDS).

Our Company is consistent in supplying of quality products round the year. Our products comply with requisite safety standards. We are a quality conscious company. We are constantly striving to expand our line of products and we are always looking for complementary products that will add to our range of products.

Product/Service Offering: Our Company primarily has following Products:

- i) Capsules
- ii) Ointment
- iii) Suspension
- iv) Dry Powder Sachet
- v) Tablet

For further details, please see “Our Business” on page 102.

Intellectual Property, if any

The Company has availed several Trademark and word mark of the Company. For more details, refer “Government and Other Approvals” at page 193 of Red Herring Prospectus.

Market Share: Not ascertainable

Manufacturing plant, if any: N.A.

Employee Strength: As on March 31, 2024, the Company has employed 112 employees at various levels of the Organization.

BOARD OF DIRECTORS				
Sr. No.	Name	Designation (Independent / Whole time / Executive / Nominee)	Experience & Educational Qualification	Other Directorships
1.	Bal Kishan Gupta	Chairman and Managing Director	<p>Experience: He has more than 35 years of experience in manufacturing, exports and distribution of pharmaceutical products. He has been associated with our Company since inception and is responsible for expanding business horizons, corporate strategy, leadership and management, financial performance across verticals, stakeholder relations, innovation and growth, identifying new opportunities and risk management of our Company. He has been General Secretary of IDMA (India Drugs Manufactures Associations), it is the most reputed association in India for pharmaceutical manufactures.</p> <p>Qualification: He is a Bachelor of Arts.</p>	<p>Indian Companies</p> <p>1. Redline Health Care Private Limited</p> <p>Foreign Companies</p> <p>- NIL</p>
2.	Ashutosh Gupta	Whole Time Director	<p>Experience: He has experience in this field of 18 years he earlier worked with listed Company names Medicamen Biotech Limited and later joined Medicamen Organics Limited. He has been awarded with the degree of Honorary Doctorate in contribution in Export of Pharma Industry in the year 2021. He has been Chairman of Pharmexcil (Pharmaceuticals Export Promotion Council of India) from 2014-2016, a Government of India Council, specifically created for promotion of pharmaceutical exports from India.</p> <p>Qualification: He hold a degree of Bachelor of Business Administration.</p>	<p>Indian Companies</p> <p>1. Dreamax Healthcare Private Limited</p> <p>2. Redline Health Care Private Limited</p> <p>3. Easy Technosoft Private Limited</p> <p>4. India Brazil Chamber of Commerce</p>
3.	Shailesh Harimohan Gaur	Executive Director	<p>Experience: She has around 32 years of experience managing the affairs of the Company.</p> <p>Qualification: He holds the degree of Bachelor of Science and Master of Business Administration (MBA) awarded by National Institute of Business Management</p>	<p>Indian Companies</p> <p>NIL</p>
4.	Rakesh Kumar	Independent Director	<p>Experience: He is owner of M/s A.R. Associates, a proprietary concern dealing in preparation of</p>	<p>Indian Companies</p> <p>NIL</p>

			financial statements, tax consultancy, legal advice and audit of balance-sheet, etc. He prepares returns, represents clients before the tax authorities and provides general tax advice to his clients. He is into this business for the last 25 years and is very successful in his profession Qualification: He is a Law Graduate	
5.	Rajinder Kumar Gupta	Independent Director	Experience: He has more than four decades of expertise in the field of Finance, assessing business risk, capital market, and organizational transformation. Qualification: he is a Commerce Postgraduate from Delhi University .	Indian Companies - NIL
6.	Sneh Gaur	Non-Executive Director	Experience: She has around 8 years working experience as a microbiologist. She also had a good experience in IT sector. Qualification: She holds Bachelor of Science/Diploma in computer management—DOEAC -A Level.	Indian Companies NIL
7.	Sachin Gupta	Independent Director	Experience: Having more than two decades of experience, he is a seasoned financial professional well-versed in financial control, reporting, and project management. His diverse career includes roles in various multinational companies where he acquired extensive expertise in overseeing financial reporting and control function Qualification: He holds the degree of Chartered Financial Analyst (CFA), B. Com (H) and Master of Financial Analysis	NIL

For further details in relation to our Board of Directors, see “*Our Management*” beginning on page 140 of the RHP.

OBJECTS OF THE OFFER

Details of means of finance –

The fund requirements for each of the objects of the Issue are stated as follows:

(in ₹ lakhs)

Particulars	Total estimated amount
Funding of expenses proposed to be incurred towards Product registration in the international markets;	Upto 300.00
Plant updation and increase in production capacity	Upto 225.00
Funding working capital requirements of our Company	Upto 400.00
General corporate purposes ⁽¹⁾	[●]
Total⁽¹⁾	[●]

⁽¹⁾ To be determined upon finalisation of the Issue Price and updated in the Red Herring Prospectus / Prospectus prior to filing with the RoC.

The amount utilised for general corporate purposes shall not exceed 25% of the Gross Proceeds.

Details and reasons for non-deployment or delay in deployment of proceeds or changes in utilization of issue proceeds of past public issues / rights issue, if any, of the Company in the preceding 10 years: Nil

Name of monitoring agency, if any – Not Applicable

Terms of Issuance of Convertible Security, if any - Not Applicable

Shareholding Pattern:

Sr. No.	Particulars	Pre Issue number of shares	% Holding of Pre issue
1.	Promoter and Promoter Group	69,83,900	81.21%
2.	Public	16,16,100	18.79%
	Total	86,00,000	100%

Number/amount of equity shares proposed to be sold by selling shareholders. – Not Applicable.

RESTATED FINANCIALS STATEMENT

(All amounts in Indian Rupees in Lakhs, unless otherwise stated)

Particulars	March 31, 2024	March 31, 2023	March 31, 2022
Share Capital	860	600	600
Net Worth ⁽¹⁾	1518.40	897.99	801.06
Revenue from Operation	2,527.17	2,214.71	2,097.52
Restated profit for the year	240.41	96.93	10.14
Restated Basic Earnings per Share ⁽²⁾	3.18	1.62	0.17
Restated Diluted Earnings per Share ⁽³⁾	3.18	1.62	0.17
Restated Net Asset Value per Share ⁽⁴⁾	17.66	14.97	13.35
Total Borrowings ⁽⁵⁾	1265.65	1179.50	1024.57

1. Net Worth is calculated as the sum of equity share capital and other equity attributable to owners of the Company;
2. Basic EPS = Net Profit after tax, as restated, attributable to equity shareholders divided by weighted average no. of equity shares outstanding during the year/ period
3. Diluted EPS = Net Profit after tax, as restated, attributable to equity shareholders divided by weighted average no. of diluted equity shares outstanding during the year/ period.
4. Net Asset Value per share = Net worth attributable to the owners of the company divided by the numbers of shares outstanding as at year end.
5. Total borrowings is the sum of short-term borrowings and long-term borrowings

INTERNAL RISK FACTORS

(Minimum 5 and maximum 10 risk factors to be specified)

The below mentioned risks are top 7 risk factors as per the RHP. (500 word limit in total)

1. Our Company, its Directors and its Promoters are party to certain litigation and claims. These legal proceedings are pending at different levels of adjudication before various forums and regulatory authorities. Any adverse decision may make us liable to liabilities/penalties and may adversely affect our reputation, business and financial status.

2. We require a number of approvals, licenses, registrations and permits in the ordinary course of our business and any failure or delay in obtaining the same in a timely manner may adversely affect our operations.
3. Our business activities are exposed to fluctuations in the prices of raw materials.
4. The Company is dependent on few numbers of customers for sales. Loss of any of this large customer may affect our revenues and profitability.
5. The Company is dependent on few suppliers for purchase of product. Loss of any of these large suppliers may affect our business operations.
6. The restated examination report by our peer review auditor on Restated Financial Statements has provided a matter of emphasis paragraph for the company has not accounted for interest provisions as per MSMED Act, 2006.
7. Our Registered Office and our factories are located on premises which are not owned by us and has been obtained on lease basis. Disruption of our rights as licensee/ lessee or termination of the agreements with our licensors/ lessors would adversely impact our operations and, consequently, our business, financial condition and results of operations.

For further details on 'Risk Factors' please refer page no. 27 of the Red Herring Prospectus.

SUMMARY OF OUTSTANDING LITIGATIONS, CLAIMS AND REGULATORY ACTION

A summary of outstanding litigation proceedings involving our Company, our Promoters, Directors and our Group Company, as on the date of this Red Herring Prospectus as disclosed in the section titled ***“Outstanding Litigation and Material Developments”*** in terms of the SEBI (ICDR) Regulations and the Materiality Policy is provided below:

Nature of Cases	Number of Cases	Total Amount Involved (in Rs. Lakhs)
Proceedings against our Company		
Criminal	8	15.58
Civil	Nil	Nil
Outstanding actions by Regulatory and Statutory Authorities	Nil	Nil
Tax	15	197.19
Proceedings by our Company		
Criminal	1	5.70
Civil	Nil	Nil
Proceedings against our Director		
Criminal	Nil	Nil
Civil	1	Not ascertainable
Outstanding actions by Regulatory and Statutory Authorities	Nil	Nil
Tax	Nil	Nil
Proceedings by our Director		
Criminal	Nil	Nil
Civil	Nil	Nil
Proceedings against our Promoter		
Criminal	Nil	Nil
Civil	1	Not ascertainable
Outstanding actions by Regulatory and Statutory Authorities	Nil	Nil
Tax	Nil	Nil
Proceedings by our Promoter		
Criminal	Nil	Nil
Civil	2	Not ascertainable
Proceedings against our Group Companies		
Criminal	Nil	Nil
Civil	Nil	Nil
Outstanding actions by Regulatory and Statutory Authorities	Nil	Nil
Tax	11	32.38
Proceedings by our Group Companies		
Criminal	Nil	Nil
Civil	Nil	Nil

For further details, see “Outstanding Litigation and Material Developments” on page 181 of the RHP.

- A. Brief details of top 5 material outstanding litigations against the company and amount involved-NIL
- B. Regulatory Action, if any - disciplinary action taken by SEBI or stock exchanges against the Promoters in last 5 financial years including outstanding action, if any (200 – 300- word limit in total) - NIL
- C. Brief details of outstanding criminal proceedings against Promoters (300- 500-word limit in total) –
1. *The State of Andhra Pradesh vs. Medicamen Organics Limited and Hukum Chand Sharma - SC.MU/221/2023*

The State of Andhra Pradesh ("**Complainant**") filed a complaint bearing no. SC.MU/221/2023 ("**Complaint**") against Medicamen Organics Limited ("**MOL**") and Hukum Chand Sharma ("**Accused No. 2**") (Mol and Accused No. 2 collectively referred to as the "**Accused**") before the Honorable Court of First Additional Chief Metropolitan Magistrate Court, Vishakhapatnam (the "**Court**"). This Complaint was filed against the Accused because the Complainant claims that the Accused have contravened Section 18(a)(i) read with Section 17-B and Section 18(a)(i) r/w Section 16(1)(a) of the Act. The matter is currently pending and the next hearing date is December 3, 2024.

2. *State of Punjab vs. Bal Kishan Gupta, Ashutosh Gupta, Hukum Chand Sharma and Medicamen Organics Limited - COMA/1076/2022*

The State of Punjab ("**Complainant**") filed a complaint bearing no. COMA/1076/2022 ("**Complaint**") against Bal Kishan Gupta ("**Accused No. 1**"), Ashutosh Gupta ("**Accused No. 2**"), Hukum Chand Sharma ("**Accused No. 3**") and Medicamen Organics Limited, ("**MOL**") (Accused No. 1, Accused No. 2, Accused No. 3 and MOL collectively referred to as the "**Accused**") before the Honorable Court of Chief Judicial Magistrate, Bathinda. This Complaint has been filed because the Complainant claims that the Accused have contravened Section 18(a)(i) read with Section 17-B of the Act. The matter is currently pending and the next hearing date is July 4, 2024.

3. *Harsh Manglik vs. Medicamen Organics Limited - Criminal Case/2169/2023*

Harsh Manglik ("**Complainant**") filed a criminal case bearing no. 2169/2023 against Medicamen Organics Limited ("**MOL**") before the Court of Additional Chief Judicial Magistrate, Roorkee. According to the Complainant, MOL was liable to pay an amount of ₹1,13,280 for certain goods purchased in the year 2022-23. MOL issued a cheque dated February 15, 2023 for the required amount, however, upon depositing the cheque, MOL's Bank returned it to the Complainant's bank with a note of "Payment Stopped by Drawer" on May 4, 2023. Hence, the Complainant has filed this case under Section 138 of the Negotiable Instruments Act, 1881. The matter is still pending. The next date of the matter is July 4, 2024

4. *Drug Inspector vs. Medicamen Organics Limited, Ashutosh Gupta, Bal Kishan Gupta and Hukum Chand Sharma – CC/713/2023*

The case has been filed by the Drug Inspector in the Judicial First Class Magistrate Court, Thalassery bearing no. CC/713/2023 against Medicamen Organics Limited, Ashutosh Gupta, Bal Kishan Gupta and Hukum Chand Sharma on June 6, 2023. The Company has not been served with any summons as on date, the matter is pending for re-issuance of Summons. The next date of the matter is July 23, 2024.

5. *Harsh Manglik vs. Medicamen Organics Limited - Criminal Case/2321/2023*

Harsh Manglik ("**Complainant**") filed a criminal case bearing no. 2321/2023 against Medicamen Organics Limited ("**MOL**") before the Court of Additional Chief Judicial Magistrate, Roorkee. According to the Complainant, MOL was liable to pay an amount of Rs. 1,78,770, Rs. 1,96,470 and Rs. 1,29,387 for certain goods purchased in the year 2022-23. MOL issued cheques dated February 20, 2023, February 25, 2023 and February 25, 2023, respectively, for the required amount. However, upon depositing the cheques, MOL's Bank returned it to the Complainant's bank with a note of "Payment Stopped by Drawer" on May 19, 2023. Hence, the Complainant has filed this case under Section 138 of the Negotiable Instruments Act, 1881 and pay the aforementioned amounts along with interest to the Complainant. The matter is still pending. The next date of the matter is July 19, 2024

ANY OTHER IMPORTANT INFORMATION AS PER BRLM / ISSUER COMPANY - NIL

DECLARATION BY THE COMPANY

I hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, regulations and guidelines issued by the Government of India, and the regulations or guidelines issued by Securities and Exchange Board of India, established under Section 3 of the Securities and Exchange Board of India Act, 1992 as the case may be, have been complied with and no statement made in this Red Herring Prospectus is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, and the Securities and Exchange Board of India Act, 1992, each as amended or the rules, regulations or guidelines issued thereunder, as the case may be. I further certify that all the disclosures and statements made in this Red Herring Prospectus are true and correct.